Scienture Holdings reported Q2 2026 revenue of $343,639, a 510% sequential increase from Q1's $56,325. Gross margin reached approximately 97.7%, while operating expenses decreased 41% year-over-year to $3.0 million. The net loss narrowed 58% to $2.8 million ($0.07 per share). Cash and equivalents rose to $11.2 million from $6.7 million at year-end 2025. The company launched REZENOPY™ nasal spray for opioid overdose treatment, securing formulary coverage with a national health plan. Scienture is a specialty pharmaceutical holding company focused on the commercialization of novel products.